Tecan Group (OTCMKTS:TCHBF – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Valuation & Earnings
This table compares Tecan Group and Profound Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tecan Group | N/A | N/A | N/A | $4.27 | 56.05 |
| Profound Medical | $18.81 million | 15.92 | -$42.57 million | ($1.24) | -6.65 |
Insider & Institutional Ownership
46.8% of Tecan Group shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for Tecan Group and Profound Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tecan Group | 0 | 0 | 0 | 0 | 0.00 |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
Profound Medical has a consensus target price of $11.50, indicating a potential upside of 39.56%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Tecan Group.
Profitability
This table compares Tecan Group and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tecan Group | N/A | N/A | N/A |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Summary
Profound Medical beats Tecan Group on 7 of the 12 factors compared between the two stocks.
About Tecan Group
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution. It provides PARAMIT, a contract design and manufacturing service. The company operates in Switzerland, Europe, Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Tecan Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tecan Group and related companies with MarketBeat.com's FREE daily email newsletter.
